DUBLIN–(BUSINESS WIRE)–The “Global Cancer Biomarkers Market Analysis 2019” report has been added to ResearchAndMarkets.com’s offering.
The Global Cancer Biomarkers market is expected to reach $37.99 billion by 2026 growing at a CAGR of 14.2% from 2018 to 2026.
Factors such as rise in technological advancements and increase in Incidence of Cancer diseases are driving the market growth. Though, high capital investment and technical issues related to sample collection and storage are projected to inhibit the growth of the market. Moreover, emerging economies and personalized medicine may provide ample opportunities for the market growth.
By biomarker type, protein biomarkers segment acquired significant growth in the market is mainly attributed to the tremendous capability of protein biomarkers in cancer detection, diagnostics, prognostics, and clinical & therapeutic applications; and minimal cost of the protein biomarker tests as contrasted with genetic biomarker tests. The rising focus of pharmaceutical organizations towards the discovery of protein biomarkers is additionally expected to fuel the development of this market during the forecast period.
The key vendors mentioned are Qiagen N.V., Thermo Fisher Scientific, GE Healthcare, Roche Diagnostics, Abbott Laboratories, Illumina, Danaher Corporation, Agilent Technologies, Sysmex Corporation, Merck & Co., Quest Diagnostics, Becton, Dickinson and Company, Hologic, Myriad Genetics, Bio-Rad Laboratories and Biomrieux S.A.
Key Questions Answered in this Report
- How this market evolved since the year 2016
- Market size estimations, forecasts and CAGR for all the segments presented in the scope
- Key Market Developments and financials of the key players
- Opportunity Analysis for the new entrants
- SWOT Analysis of the key players
- Fastest growing markets analysed during the forecast period
Key Topics Covered
1 Market Synopsis
2 Research Outline
2.1 Research Snapshot
2.2 Research Methodology
2.3 Research Sources
2.3.1 Primary Research Sources
2.3.2 Secondary Research Sources
3 Market Dynamics
3.1 Drivers
3.2 Restraints
4 Market Environment
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Cancer Biomarkers Market, By Category
5.1 Introduction
5.2 Cancer Biomakers of Disease
5.3 Cancer Biomakers of Exposure
6 Global Cancer Biomarkers Market, By Method
6.1 Introduction
6.2 Assay Development
6.3 Biomarkers and Testing
6.4 Sample Preparation
7 Global Cancer Biomarkers Market, By Biomarker Type
7.1 Introduction
7.2 Cancer Antigen 15-3 (CA 15-3)
7.3 Cancer Antigen 27-29 (CA27-29)
7.4 Carbohydrate Antigen 19-9 (CA 19-9)
7.5 Carcinoembryonic antigen (CEA)
7.6 Epigenetic Biomarkers
7.7 Genetic Biomarkers
7.8 Glass Transition Temperature (Tg)
7.9 Glyco-biomarkers
7.10 Glycomic Biomakers
7.11 Glycoprotein Biomarkers
7.12 Human Chorionic Gonadotropin (Hcg)
7.13 Human Epidermal Growth Factor Receptor 2 (HER2)
7.14 Human Epididymis Protein 4 (HE4)
7.15 Metabolic Biomakers
7.16 Microsatellite Instability (MSI) / Measles, Mumps and Rubella (MMR)
7.17 Protein Biomarkers
7.18 Proteomic Biomarkers
7.19 Risk of Ovarian Malignancy Algorithm (ROMA)
7.20 Tumor Mutational Burden (TMB)
7.21 Tumor-Infiltrating Lymphocytes (TILs)
8 Global Cancer Biomarkers Market, By Cancer Type
8.1 Introduction
8.2 Bladder Cancer
8.3 Blood Cancer
8.4 Breast Cancer
8.5 Cervical Cancer
8.6 Colorectal Cancer (CRC)
8.7 Kidney Cancer
8.8 Leukemia
8.9 Liver Cancer
8.10 Lung Cancer
8.11 Melanoma
8.12 Non-Hodgkin’s Lymphoma
8.13 Ovarian Cancer
8.14 Prostate Cancer
8.15 Stomach Cancer
8.16 Thyroid Cancer
9 Global Cancer Biomarkers Market, By Technology
9.1 Introduction
9.2 Bioinformatics
9.3 Cytogenetics-based Tests
9.4 Imaging Technologies
9.5 Immunoassays
9.6 IVD Multivariate Index Assays
9.7 Omic technologies
10 Global Cancer Biomarkers Market, By Test Type
10.1 Introduction
10.2 Alpha-Fetoprotein (AFP) Tests
10.3 Anaplastic Lymphoma Receptor Tyrosine Kinase Gene (ALK) Tests
10.4 BReast CAncer gene (BRCA) Tests
10.5 Cancer Antigen (CA) Tests
10.6 Carcinoembryonic Antigen (CEA) Tests
10.7 Circulating Tumor Cell (CTC) Tests
10.8 Companion Diagnostic Tests (CDx)
10.9 Estimated Glomerular Filtration Rate (EGFR) Mutation Tests
10.10 Human Epidermal Growth Factor Receptor 2 (HER2) Tests
10.11 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation Tests
10.12 Laboratory Developed Tests (LDTs)
10.13 Prostate-specific Antigen (PSA) Tests
11 Global Cancer Biomarkers Market, By Analytical Technique
11.1 Introduction
11.2 Immunohistochemistry (IHC)
11.3 Next Generation Sequencing (NGS)
11.4 Polymerase Chain Reaction (PCR)
12 Global Cancer Biomarkers Market, By Product
12.1 Introduction
12.2 cDNA clone based
12.3 ELISA pair sets based
12.4 RNA based
12.5 Tumor suppressor based
13 Global Cancer Biomarkers Market, By Application
13.1 Introduction
13.2 Development and Drug Formulation
13.3 Development of Molecular Diagnostics
13.4 Disease Diagnostics
13.5 Drug Discovery and Development
13.6 Personalised Medicine
13.7 Predictive
13.8 Prognostics
13.9 Research and Development
13.10 Risk Assessment
13.11 Therapeutic
14 Global Cancer Biomarkers Market, By End-user
14.1 Introduction
14.2 Academic and Cancer Research Institutes
14.3 Ambulatory Surgical Centers
14.4 Cancer Diagonostic Centers and Reasearch Laboratories
14.5 Clinic Laboratories
14.6 Contract Research Organizations(CRO)
14.7 Healthcare IT/Big Data Companies
14.8 Hospitals
14.9 Pharma & Biotech Companies
15 Global Cancer Biomarkers Market, By Geography
15.1 Introduction
15.2 North America
15.3 Europe
15.4 Asia-Pacific
15.5 South America
15.6 Middle East & Africa
16 Strategic Benchmarking
17 Vendors Landscape
17.1 Abbott Laboratories
17.2 Agilent Technologies
17.3 Becton, Dickinson and Company
17.4 bioMerieux S.A.
17.5 Bio-Rad Laboratories
17.6 Danaher Corporation
17.7 GE Healthcare
17.8 Hologic
17.9 Illumina
17.10 Merck & Co
17.11 Myriad Genetics
17.12 Qiagen N.V.
17.13 Quest Diagnostics
17.14 Roche Diagnostics
17.15 Sysmex Corporation
17.16 Thermo Fisher Scientific
For more information about this report visit https://www.researchandmarkets.com/r/gmcu0n
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900